Home Monofocal IOLs HOYA Vivinex iSert
Vivinex iSert left

HOYA Vivinex™ iSert® IOL

Models: XC1 | XY1

Cataract surgery simplified.
The glistening-free hydrophobic Vivinex IOL offers unprecedented visual clarity. Preloaded in the Vivinex™ iSert® injector.
Glistening-free material

Made from hydrophobic acrylic IOL material. Delivery via the preloaded Vivinex™ iSert® injector system.

Aspheric optic design

Proprietary aspheric optic design for improved image quality.

Active oxygen processing

Active oxygen processing treatment and sharp optic edge to reduce PCO.

HOYA Vivinex™ iSert® benefits:
  • Fully preloaded 100% hydrophobic aspheric 1 piece IOL
  • Simple and easy implantation into the capsular bag
  • MICS 2.0mm incision
  • Glistening-free hydrophobic acrylic IOL material
  • Proprietary aspheric optic design for improved image quality
  • Active oxygen processing treatment and sharp optic edge to reduce PCO
HOYA Vivinex™ iSert® illustration


Download
Technical specifications
Description & Technical Specs
HOYA Vivinex iSert. The preloaded, monoblock, aspheric, UV-absorbing IOL.
Model
XC1 | XY1
Optic material
Hydrophobic acrylic Vivinex™
with UV-filter (Model XC1)
with UV- and blue light filter (Model XY1)
Optic design
Aspheric Design with sharp textured optic edge
Haptic design
Textured-rough haptic surface
Haptic material
Hydrophobic acrylic Vivinex™ with UV-Filter (Model XC1)
Diameter (optic/OAL)
6.00 mm / 13.00 mm
Power
+6.00 to +30.00 D (in 0.50 D increments)
Injector
Vivinex™ iSert® preloaded
Nominal A-Constant
118.9
Front injector tip outer diameter
1.70 mm
Optimised constants
Haigis a0 = -0.8394 a1 = 0.2023a2 = 0.2272
Hoffer Q pACD = 5.7058
Holladay 1 sf = 1.9432
SRK/T A = 119.219

The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon’s own experience.

Optimised Optical constants Source: https://iolcon.org Calculated from 910 clinical results based on caucasian patient as of August 22, 2019.